Skip to main content
Figure 5 | Molecular Pain

Figure 5

From: p300 exerts an epigenetic role in chronic neuropathic pain through its acetyltransferase activity in rats following chronic constriction injury (CCI)

Figure 5

ChIP assays in shRNA treated and p300 acetyltransferase inhibitor treated rats . Reactions were performed with normal mouse IgG or anti-p300 antibodies. Real time PCR was used to quantify the enrichment of p300 promoter region of the cox-2 gene. Comparison between rats with different treatments: *P < 0.05 vs. sham-operated group; #P < 0.05 vs. NS and NC-treated groups. ΔP < 0.05 vs. C37-treated group. S: sham-operated rats; NS: NS-treated CCI rats; NC: LV-NC-treated CCI rats; shp300: LV-shp300-treated CCI rats. C37: C37-treated CCI rats; C646:C646-treated CCI rats.

Back to article page

Molecular Pain

ISSN: 1744-8069

Contact us